

Date: February 8, 2019

The Secretary,
BSE Limited
Floor 25, Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

Dear Sirs,

Sub: Unaudited Financial Results for the Quarter and Nine Months ended 31.12.2018
Ref: Scrip Code: 526783

We request your kind attention to the above subject and references. We wish to inform you that at the Board Meeting held today, the Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2018 was taken on record and approved by the Board of Directors of the Company. We enclose herewith the Un-Audited Financial Results and the Auditors' Limited Review Report.

As per the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has also made arrangements for release of the Unaudited Results in the Newspapers.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For **DR. AGARWAL'S EYE HOSPITAL LIMITED**



DR. AMAR AGARWAL
CHAIRMAN CUM MANAGING DIRECTOR

Registered Office

3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Near Asan Memorial School, Chennai - 600 006.
Tel: 91-44-3991 6600 Fax: 91-44-3991 6645
Corporate ID Number: L85110TN1994PLC027366 GST No. 33AAACD2373G1Z2
Email: dragarwal@vsnl.com | Website: www.dragarwal.com

INDEPENDENT AUDITOR'S REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **DR. AGARWAL'S EYE HOSPITAL LIMITED** ("the Company"), for the Quarter and Nine months ended 31 December 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement has not been in accordance with the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)



Jaideep S Trasi
Partner
(Membership No. 211095)





Dr. Agarwal's Eye Hospital Limited
 Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006
 Phone No. 91-44-39916669, Website : www.dragarwal.com, E-mail : investor@dragarwal.com, CIN : L85110TN1994PLC027366
 Statement of Unaudited Financial Results for the Quarter and Nine Months Ended 31 December 2018

S.No.	Particulars	(Amount Rs. in Lakhs except earnings per share data)					
		Quarter Ended		Nine Months ended		Year Ended	
		31-Dec-18	30-Sep-18	31-Dec-17	31-Dec-18	31-Dec-17	31-Mar-18
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Income						
	(a) Revenue from Operations	4,065.76	4,395.01	3,460.78	12,899.87	11,574.17	15,332.13
	(b) Other Income	62.31	32.50	95.36	138.27	163.55	230.00
	Total Income	4,128.07	4,427.51	3,556.14	13,038.14	11,737.72	15,562.13
2	Expenses						
	(a) Purchase of Stock-in-Trade (Refer Note 4)	610.20	425.27	319.81	1,655.32	1,373.04	1,886.47
	(b) Changes in Inventories of Stock-in-Trade - (Increase) / Decrease	20.51	69.26	98.91	(33.76)	(61.89)	(81.82)
	(c) Consumables (Refer Note 4)	459.16	420.37	392.61	1,288.31	1,143.90	1,541.74
	(d) Consultancy Charges	549.38	603.57	518.00	1,733.63	1,490.62	2,002.75
	(e) Employee Benefit Expenses	956.50	891.69	895.22	2,600.64	2,456.77	3,198.03
	(f) Finance Costs	58.24	64.89	57.59	170.50	163.54	259.04
	(g) Depreciation and Amortisation Expense	277.25	239.48	269.54	738.95	738.95	978.18
	(h) Rent	481.04	465.77	437.89	1,368.60	1,274.95	1,717.98
	(i) Other Expenses	680.93	649.76	780.86	2,027.42	1,995.41	2,713.67
	Total Expenses	3,993.31	3,830.06	3,760.43	11,566.66	10,575.20	14,226.04
3	Profit before Exceptional Items and Tax (1-2)	134.76	597.45	(204.29)	1,471.48	1,162.52	1,336.09
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	134.76	597.45	(204.29)	1,471.48	1,162.52	1,336.09
6	Tax Expense	(11.30)	200.80	(26.50)	425.30	497.80	644.35
	- Current Tax (including prior years)			(44.98)	10.82	(96.19)	14.22
	- Deferred Tax	31.40	(1.05)				
7	Net Profit for the period (5-6)	114.66	397.70	(132.81)	1,035.36	760.91	677.52
8	Other Comprehensive Income						
	(a) Items that will not be reclassified to the Statement of Profit and Loss						
	- Actuarial loss on defined benefit obligation	(7.90)	(8.81)	(8.26)	(26.26)	(24.87)	(38.19)
	- Tax on items that will not be reclassified to the Statement of Profit and Loss	2.29	2.57	2.86	7.64	8.61	11.12
	(b) Items that will be reclassified to the Statement of Profit and Loss						
	- Tax on items that will be reclassified to the Statement of Profit and Loss	-	-	-	-	-	-
9	Total Other Comprehensive Loss (net of tax)	(5.61)	(6.24)	(5.40)	(18.62)	(16.26)	(27.07)
10	Total Comprehensive Income (7+8)	109.05	391.46	(138.21)	1,016.74	744.65	650.45
11	Paid-up equity share capital (Face value Rs. 10/- each)	470.00	470.00	470.00	470.00	470.00	470.00
12	Reserves (Other Equity)						
	Earnings Per Equity Share (EPS) (of Rs. 10/- each)						
	(a) Basic	2.44	8.46	(2.83)	22.03	16.19	14.42
	(b) Diluted	2.44	8.46	(2.83)	22.03	16.19	14.42
		(not Annualised)	(not Annualised)	(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)

- Notes:**
- The above unaudited financial results have been reviewed by the Audit Committee, approved and taken on record by the Board of Directors in their Meeting held on 8 February 2019. The above results for the quarter and nine months ended 31 December 2018 has also been subject to limited review by the Statutory Auditors of the Company.
 - The Company operates in a single segment i.e. "Eye Care related Sales and Services" and hence, does not have any additional disclosures to be made under Ind AS 108 - Operating Segments.
 - Effective 1 April 2018, the Company has adopted IND AS 115 'Revenue from Contracts with Customers'. The application of IND AS 115 did not have any material impact on the financial results of the Company.
 - Purchase of Stock-in-Trade previously classified under 'Consumables for the quarters ended 30 June 2018 and 30 September 2018 amounting to Rs. 112.75 lakhs and Rs. 185.95 lakhs, respectively have been reclassified.



By order of the Board
 Dr. Amar Agarwal
 Chairman & Managing Director
 DIN No. 00435684

Place : Chennai
 Date : 8 February 2019